2025 Partners
Dec Group
Expertise Partner
Dec Group is the leading global provider of contained powder handling systems and is recognized as a world-leading expert in process containment technologies. The depth of Dec’s knowledge and their ability to develop innovative new technologies as well as the recent acquisition of containment and aseptic solution provider ExtractTechnology make them an invaluable partner for both multinationals and specialists.
Olon
Innovation Partner
Thanks to continuous investments in our integrated manufacturing network, Olon offers flexible capacity to develop and produce highly potent APIs (HPAPIs), including innovator molecules and generics, for all stages of clinical development as well as commercial supply.
Olon has manufacturing sites in Europe and the USA for HPAPIs, each equipped with multiple reactors of varying sizes and capabilities. We also have decades of experience in lifecycle management for a portfolio of high containment production processes, which is among the most extensive worldwide.
At Olon’s Global HQ near Milan, Italy, we have recently completed a manufacturing line containing reactors capable of producing HPAPIs in batches ranging from 30 to 300 kg under OEB5 containment (OEL 1 μg/m3). This expansion can enable us to serve our customers along all stages of process development, as well as facilitate technology transfer across our global manufacturing sites.
We have also built and qualified a new facility dedicated to producing Ultra-Potent compounds, such as payloads and payload-linkers for antibody-drug conjugates (ADCs). Our Ultra-Potency facility opened in late 2024 at our Global HQ and can operate at OEB6 containment (OEL 10 ng/m3).
Olon is among the select few API suppliers offering a broad range of globally integrated capabilities and quality management systems (QMS) necessary to support customers from early clinical phase through industrialization, from grams to hundreds of kilograms per batch. We look forward to helping drug developers deliver essential, groundbreaking medicines to the global patient population.
